The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients with Head and Neck Cancer Undergoing Radiation Therapy
- Conditions
- Head and Neck Squamous Cell CarcinomaMalignant Head and Neck Neoplasm
- Interventions
- Other: Medical Device Qardio® smart scale Usage and EvaluationOther: Questionnaire Administration
- Registration Number
- NCT05457478
- Lead Sponsor
- OHSU Knight Cancer Institute
- Brief Summary
This clinical trial studies the use of "smart" body-weight scales to monitor weight and nutrition among patients with head and neck cancer undergoing radiation therapy. Malnutrition affects 30-50% of patients diagnosed with head and neck cancer, and approximately 30% of patients have malnutrition prior to diagnosis. "Smart" body weight scales can possibly make self-weighing easier, faster, and more accurate through weight recordings through mobile applications available for "smart" scales. This has the potential to maximize nutritional guidance through quick weight updates, possibly delaying or removing the use of patient enteral feeding (tube feeding). By avoiding or minimizing the use of enteral feeding during radiation therapy, the risk of long-term tube dependence and swallowing ability complications may be reduced.
- Detailed Description
PRIMARY OBJECTIVE:
I. To determine the feasibility of "smart" body scales in patients undergoing radiation therapy for head and neck cancer.
SECONDARY OBJECTIVE:
I. MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, overall pain scores, and weight loss percentage.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients weigh themselves daily using the "Smart" scale over 5-8 weeks during standard radiation therapy.
COHORT II: Patients do not weigh themselves using the "Smart" scale during standard radiation therapy.
After completion of study intervention, patients are followed up within 2 weeks and 3 months post-radiation therapy.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2
- Participants must have a histologically confirmed malignancy whereby pursual of radiation therapy has potential curative benefits for the patient.
- Criteria for selection of head and neck malignancies include squamous cell carcinoma.
- Ability to understand and the willingness to sign a written informed consent document.
- For the intervention group, the ability to properly utilize a "smart" body weight scale after appropriate training has been provided. This includes access to wireless internet which can be paired with the "smart" body weight scale to transmit weight scale data.
-
Do not meet the criteria for histologically confirmed malignancies.
-
Refuse or do not pursue radiation therapy for curative benefit of their malignancy.
-
Who do not understand or are unwilling to sign a written informed consent document.
-
For the intervention group, the inability to utilize or pair their "smart" body weight sales to wireless internet.
-
Members of vulnerable populations as below
-
Pregnant women, children, prisoners, neonates, and decisionally impaired adults will not be included in this study. Excluding vulnerable populations, all patients who are receiving or seeking medical care at Oregon Health & Science University (OHSU) for their head and neck cancer and meet inclusion criteria will be invited to participate in this study. Potential participants will be approached by a member of the clinic staff and will be asked to review a copy of the informed consent form prior to being seen by a treating physician. The investigator, or other qualified, designated healthcare provider will review the informed consent form with potential participants and address any questions or concerns prior to obtaining written informed consent for participation in this study. The investigator or other qualified, designated healthcare provider will also address any future questions or concerns of the participant.
- Only individuals who have provided directly their written informed consent for participation in this study and meet inclusion criteria will be placed in the study. The participation of patients who are mentally incapacitated (e.g., comatose, unresponsive) will not be sought
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort I ('Smart" scale weighing) Medical Device Qardio® smart scale Usage and Evaluation Patients weigh themselves daily using the "Smart" scale over 5-8 weeks during standard radiation therapy. Cohort I ('Smart" scale weighing) Questionnaire Administration Patients weigh themselves daily using the "Smart" scale over 5-8 weeks during standard radiation therapy. Cohort 2 (no weighing) Questionnaire Administration Patients do not weigh themselves using the "Smart" scale during standard radiation therapy.
- Primary Outcome Measures
Name Time Method Adherence to treatment Up to 8 weeks Will include continuous variables (number of times participant stepped on the scale). Standard statistical methods will be utilized to analyze cohort data, while also accounting for missing unused, or spurious data.
- Secondary Outcome Measures
Name Time Method MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire scores Baseline up to 3 months post-radiation therapy The MDASI-HN has 13 core symptoms that is scored, at their worst over the last 24 hours, on a 0-10 numeric rating scale. A "0" means that a symptom is not present and a "10" is "as bad as you can imagine." Standard statistical methods will be utilized to analyze cohort data, while also accounting for missing unused, or spurious data.
Overall pain scores Up to 3 months post-radiation therapy Pain scores will be on a numeric rating scale, with lower numbers indicating lower pain values. Standard statistical methods will be utilized to analyze cohort data, while also accounting for missing unused, or spurious data.
Weight loss percentage Up to 3 months post-radiation therapy Standard statistical methods will be utilized to analyze cohort data, while also accounting for missing unused, or spurious data.
Trial Locations
- Locations (2)
Mid-Atlantic Permanente Medical Group
🇺🇸Rockville, Maryland, United States
OHSU Knight Cancer Institute
🇺🇸Portland, Oregon, United States